View Exam | PowerPak

1. Which of the following are believed to be the dominant phyla in the human gut that prevent the proliferation of C. difficile infection?

A. Actinobacteria and Proteobacteria B. Bacteroidetes and Firmicutes C. Bacteroidetes and Proteobacteria D. Cyanobacteria and Firmicutes

2. Which of the following best describes recommendations for the treatment of adults with an initial severe episode of C. difficile infection in the 2017 IDSA/SHEA clinical practice guidelines?

A. Metronidazole, vancomycin, and fidaxomicin are recommended with no preference for any agent B. Metronidazole and vancomycin are recommended over fidaxomicin C. Vancomycin and fidaxomicin are recommended over metronidazole D. Metronidazole is recommended over vancomycin and fidaxomicin

3. Which of the following accurately describes differences between the use of fidaxomicin and vancomycin as antimicrobial therapy for an initial episode of C. difficile?

A. Development of drug resistance is more common with fidaxomicin compared with vancomycin B. Vancomycin is approved for initial episodes of C. difficile while fidaxomicin is approved for recurrent episodes C. Fidaxomicin has twofold greater efficacy than vancomycin D. Fidaxomicin may be associated with a lower risk of recurrence than vancomycin

4. A 69-year-old woman received a course of vancomycin after testing positive for C. difficile. Her clinical symptoms resolved 8 weeks ago, but she currently presents with watery stools for 3 days. If fecal microbiota transplantation (FMT) is readily available, at what point would she be eligible for FMT?

A. After a lack of response to fidaxomicin B. After receiving antibiotic treatment for at least 2 recurrences C. After experiencing 3 or more recurrent episodes D. If a hypervirulent strain is identified

5. In an open-label, phase 2 clinical trial comparing microbiota restoration with an investigational microbiota restoration therapy RBX2660 to standard of-care oral antibiotic therapy (historical control), RBX2660 reduced recurrent C. difficile by approximately:

A. 65% when administered as a capsule B. 80% after up to two enema infusions C. 50% when administered as an enema in patients older than 65 years of age D. 50% after a single enema infusion

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following are believed to be the dominant phyla in the human gut that prevent the proliferation of C. difficile infection?

2. Which of the following best describes recommendations for the treatment of adults with an initial severe episode of C. difficile infection in the 2017 IDSA/SHEA clinical practice guidelines?

3. Which of the following accurately describes differences between the use of fidaxomicin and vancomycin as antimicrobial therapy for an initial episode of C. difficile?

5. In an open-label, phase 2 clinical trial comparing microbiota restoration with an investigational microbiota restoration therapy RBX2660 to standard of-care oral antibiotic therapy (historical control), RBX2660 reduced recurrent C. difficile by approximately:

« Return to Activity

Maintenance is scheduled for 8/7/2023 7:00 AM EST - 8:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following are believed to be the dominant phyla in the human gut that prevent the proliferation of C. difficile infection?

2. Which of the following best describes recommendations for the treatment of adults with an initial severe episode of C. difficile infection in the 2017 IDSA/SHEA clinical practice guidelines?

3. Which of the following accurately describes differences between the use of fidaxomicin and vancomycin as antimicrobial therapy for an initial episode of C. difficile?

5. In an open-label, phase 2 clinical trial comparing microbiota restoration with an investigational microbiota restoration therapy RBX2660 to standard of-care oral antibiotic therapy (historical control), RBX2660 reduced recurrent C. difficile by approximately:

« Return to Activity

Customers who Purchased
this Activity also Purchased